Key result
Targeted next-generation sequencing identified a molecular diagnosis in 85% of Indian index patients with suspected Marfan syndrome or related disorders, including 21 novel variants.
Why the study?
Marfan syndrome and related disorders carry high morbidity and mortality from aortopathies, and targeted gene panel next-generation sequencing is a powerful tool to obtain a genetic diagnosis.
Observational (n=83)
Yes
Targeted next-generation sequencing provided a molecular diagnosis in 85% of Indian patients with suspected Marfan syndrome and related disorders, expanding the known genetic spectrum with 21 novel variants.
Supports targeted NGS for suspected Marfan syndrome in Indian patients; extends variant spectrum but leaves broader validation open.
Marfan syndrome and related disorders are a group of heritable connective tissue disorders and share many clinical features that involve cardiovascular, skeletal, craniofacial, ocular, and cutaneous abnormalities. The majority of affected individuals have aortopathies associated with early mortality and morbidity. Implementation of targeted gene panel next-generation sequencing in these individuals is a powerful tool to obtain a genetic diagnosis. Here, we report on clinical and genetic spectrum of 53 families from India with a total of 83 patients who had a clinical diagnosis suggestive of Marfan syndrome or related disorders. We obtained a molecular diagnosis in 45/53 (85%) index patients, in which 36/53 (68%) had rare variants in FBN1 (Marfan syndrome; 63 patients in total), seven (13.3%) in TGFBR1/TGFBR2 (Loeys-Dietz syndrome; nine patients in total) and two patients (3.7%) in SKI (Shprintzen-Goldberg syndrome). 21 of 41 rare variants (51.2%) were novel. We did not detect a disease-associated variant in 8 (15%) index patients, and none of them met the Ghent Marfan diagnostic criteria. We found the homozygous FBN1 variant p.(Arg954His) in a boy with typical features of Marfan syndrome. Our study is the first reporting on the spectrum of variants in FBN1, TGFBR1, TGFBR2, and SKI in Indian individuals.
No takes yet. Share an insight, caveat, or question.
Nayak et al. (2021) conducted an observational in Marfan syndrome and related disorders (n=83). Next-generation sequencing was evaluated on Molecular diagnosis yield in index patients (95% CI 73-92). Targeted next-generation sequencing identified a molecular diagnosis in 85% of Indian index patients with suspected Marfan syndrome or related disorders, including 21 novel variants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: